Fang Hu

Dr. Fang Hu

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
JHJuan Huang
Juan Huang
JPJames A. Pearson
James A. Pearson
JPJian Peng
Jian Peng
YHYoujia Hu
Youjia Hu
SSSha Sha
Sha Sha
LWLi Wen
Li Wen
The incidence of type 1 diabetes (T1D) has been increasing among children and adolescents, in which environmental factors, including gut microbiota, play an important role. However, the underlying mechanisms are yet to be determined. Here, we show that patients with newly diagnosed T1D displayed not only a distinct profile of gut microbiota associated with decreased short-chain fatty acids (SCFAs) production, but also an altered IgA-mediated immunity compared with healthy control subjects. Using germ-free NOD mice, we demonstrate that gut microbiota from patients with T1D promoted different IgA-mediated immune responses compared with healthy control gut microbiota. Treatment with the SCFA, acetate, reduced gut bacteria–induced IgA response accompanied by decreased severity of insulitis in NOD mice. We believe our study provides new insights into the functional effects of gut microbiota on inducing IgA immune response in T1D, suggesting that SCFAs might be potential therapeutic agents in T1D prevention and/or treatment.

3 October 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
LLLili Liu
Lili Liu
WCWei Chen
Wei Chen
DWDan Wu
Dan Wu
FHFang Hu
Fang Hu
Context: Time-restricted eating (TRE), which restricts food intake to a limited duration of the day, is a key regimen of intermittent fasting.Objective: The aim of our study was to provide an up-to-date meta-analysis and systematic review to evaluate the efficacy of TRE on weight loss and other metabolic-related parameters in adults.Methods: We searched PubMed, EMBASE, and the Cochrane Library for relevant studies published before February 26, 2022. Study duration of TRE was at least 4 weeks. Body weight and other metabolic-related continuous parameters were described as weighted mean difference (WMD) with 95% CI.Results: Seventeen randomized controlled trials involving 899 participants were analyzed. The pooled meta-analysis has shown that TRE contributed to a significant decrease in body weight with a WMD of −1.60 kg (95% CI −2.27 to −0.93) and fat mass with WMD −1.48 kg (95% CI −1.59 to −1.38). Subgroup analysis showed that TRE could reduce body weight and fat mass especially in overweight participants with WMD −1.43 kg (95% CI −2.05 to −0.81) and −1.56 kg (95% CI −1.67 to −1.44), respectively. TRE also showed beneficial effects on the lipid spectrum in overweight participants, including decreased levels of triglyceride (WMD −12.71 mg/dL, 95% CI −24.9 to −0.52), total cholesterol (WMD −6.45 mg/dL, 95% CI −7.40 to −5.49), and low-density lipoprotein cholesterol (WMD −7.0 mg/dL, 95% CI −9.74 to −4.25). However, compared with control, TRE had no significant effects on waist circumference, body mass index, glycosylated hemoglobin, or blood pressure.Conclusion: This updated meta-analysis found that TRE may be an effective approach to improve the metabolic state of nonobese subjects, especially in overweight participants.

30 October 2021 in iScience
Verified
Journal Article
Open access
FZFeng Zhang
Feng Zhang
ZCZhinan Chen
Zhinan Chen
DWDan Wu
Dan Wu
LTLe Tian
Le Tian
QCQing Chen
Qing Chen
FHFang Hu
Fang Hu
GLP-1 analogs are a class of glucose-lowering agents with multiple benefits in diabetes, but its role in adipose tissues remains to be elucidated. The aim of this study was to determine the action of recombinant human GLP-1 (rhGLP-1) Beinaglutide (BN) in the insulin sensitivity and lipid metabolism of adipose tissues. We have shown that, after BN injection, obese mice displayed lower body weight, fat mass, and plasma lipid levels. In addition, BN promoted the insulin sensitivity in the white adipose tissues. Furthermore, we have found that the BN treatment caused significant changes in content and composition of different lipid classes, including glycerolipids, glycerophospholipids, and sphingolipids, as well as expression of genes in lipid metabolic pathways in the adipose tissues. Taken together, our data demonstrate that BN could resist HFD-induced obesity by targeting the composition of major lipid classes and the expression of genes in lipid metabolism of adipose tissues.

2 October 2024 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
WCWei Chen
Wei Chen
LLLili Liu
Lili Liu
FHFang Hu
Fang Hu
Aim: To assess the effects of vitamin D interventions on glycaemic control in subjects with type 2 diabetes (T2D). Methods: We searched PubMed, EMBASE, Web of Science and the Cochrane Library for relevant studies. Serum 25(OH)D, fasting blood glucose (FBG), HbA1c, fasting insulin and Homeostasis Model Assessment for Insulin Resistance (HOMA‐IR) were analysed. Results: We identified 39 randomized controlled trials involving 2982 subjects. Results showed a significant decline in the vitamin D group, as shown by the FBG weighted mean difference (WMD; −0.49 [95% confidence interval {CI}: −0.69 to −0.28] mmol/L), HbA1c (WMD −0.30% [95% CI: −0.43 to −0.18]), HOMA‐IR (WMD −0.39 [95% CI −0.64 to −0.14]) and insulin (WMD −1.31 [95% CI: −2.06 to −0.56] μIU/mL). Subgroup analyses indicated that the effects of vitamin D supplementation on glycaemic control depend on the dosage and duration of supplementation, baseline 25(OH)D levels and the body mass index of patients with T2D. Conclusions: Vitamin D supplementation can significantly reduce serum FBG, HbA1c, HOMA‐IR and fasting insulin levels in T2D patients; the effects were especially prominent when vitamin D was given in a short‐term, high dosage to patients with a vitamin D deficiency, who were overweight, or had an HbA1c of 8% or higher at baseline. Our study suggests that vitamin D supplements can be recommended as complementary treatment for T2D patients.

5 July 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
DWDan Wu
Dan Wu
HWHuiying Wang
Huiying Wang
LXLijun Xie
Lijun Xie
FHFang Hu
Fang Hu
The rapid increase of obesity and associated diseases has become a major global health problem. Adipose tissues are critical for whole-body homeostasis. The gut microbiota has been recognized as a significant environmental factor in the maintenance of energy homeostasis and host immunity. A growing body of evidence suggests that the gut microbiota regulates host metabolism through a close cross-talk with adipose tissues. It modulates energy expenditure and alleviates obesity by promoting energy expenditure, but it also produces specific metabolites and structural components that may act as the central factors in the pathogenesis of inflammation, insulin resistance, and obesity. Understanding the relationship between gut microbiota and adipose tissues may provide potential intervention strategies to treat obesity and associated diseases. In this review, we focus on recent advances in the gut microbiota and its actions on adipose tissues and highlight the joint actions of the gut microbiota and adipose tissue with each other in the regulation of energy metabolism.

2 October 2018 in Diabetes
Verified
Journal Article
Open access
PDF file
LHLinyun He
Linyun He
MTMowei Tang
Mowei Tang
TXTing Xiao
Ting Xiao
HLHailan Liu
Hailan Liu
WLWei Liu
Wei Liu
FHFang Hu
Fang Hu
MiRNAs are important regulators of differentiation, development and function of brown and beige fat cells. Here we identify the role of miR-199a/214 cluster in the regulation of brown and beige adipocyte development and thermogenesis in vitro and in vivo. We show that expression of the miR-199a/214 cluster is dramatically decreased during brown and beige adipocyte differentiation and in response to cold exposure or β-adrenergic receptor activation. The cluster levels are significantly up-regulated in the adipose tissues of obese mice and human subjects. Over-expression of the miR-199a/214 cluster suppresses brown adipocyte differentiation and inhibits thermogenic gene expression and mitochondrial respiration, whereas knockdown of the cluster increases thermogenic gene expression and mitochondrial function in beige adipocytes. In addition, inhibition of the miR-199a/214 cluster promotes beiging effects in vivo. We further show that miR-199a/214 suppresses brown adipocyte differentiation and beige fat development by directly targeting Prdm16 and PGC-1α, two key transcriptional regulators of adipose browning. Together, these observations reveal that the miR-199a/214 cluster is a key negative regulator of brown and beige fat development and thermogenesis.